CELIAC Archives

Celiac/Coeliac Wheat/Gluten-Free List

CELIAC@LISTSERV.ICORS.ORG

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Roy Jamron <[log in to unmask]>
Reply To:
Roy Jamron <[log in to unmask]>
Date:
Thu, 24 May 2007 07:04:31 -0400
Content-Type:
text/plain
Parts/Attachments:
text/plain (52 lines)
<<Disclaimer: Verify this information before applying it to your situation.>>

Artielle ImmunoTherapeutics is an Oregon company developing a new class of 
immunotherapy drugs called RTLs (Recombinant T Cell Receptor Ligands).  
RTLs are proteins engineered to have some specific properties of MHC II 
antigen presenting molecules.  In celiac disease MHC II molecules bind to and 
present gluten peptides to T cell receptors resulting in release of inflammatory 
chemicals and subsequent tissue destruction.  RTLs can be administered 
therapeutically to compete with and overwhelm the celiac disease specific 
MHC II molecules.  The RTLs are designed to takeup gluten peptides and 
present them to T cell receptors causing release of anti-inflammatory 
chemicals instead of inflammatory chemicals, thereby preventing and 
interrupting the destructive cascade of tissue damage associated with celiac 
disease.

RTL1000 is an RTL drug currently in human trials designed to treat multiple 
sclerosis.  Artielle is already designing an RTL drug to specifically treat celiac 
disease.  Human trials for celiac disease would follow successful MS trials.

----------
Artielle ImmunoTherapeutics
< http://www.artielle.com >
< http://www.artielle.com/DrugDev_Celiac.php >
< http://www.artielle.com/Tech_Over.php >
(See the Animation)

----------
FIRST NW PATIENT TO RECEIVE OHSU/VAMC-INVENTED MS DRUG (May 21, 
2007)
http://www.ohsu.edu/ohsuedu/newspub/052107ms.cfm

----------
Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):185-93. 
Systemic immunomodulation of autoimmune disease using MHC-derived 
recombinant TCR ligands.
Burrows GG.
Abstract:
< http://dx.doi.org/10.2174/1568010053586363 >

----------
J Biol Chem. 2001 Jun 29;276(26):24170-6. 
Design, engineering, and production of human recombinant t cell receptor 
ligands derived from human leukocyte antigen DR2.
Chang JW, Mechling DE, Bachinger HP, Burrows GG.
Free Full Text:
< http://www.jbc.org/cgi/content/full/276/26/24170 >

* * *

* All posts for product information must include the applicable country *
Archives are at: Http://Listserv.icors.org/SCRIPTS/WA-ICORS.EXE?LIST=CELIAC

ATOM RSS1 RSS2